PMID- 24319468
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20211021
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2013
DP  - 2013
TI  - Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models 
      to clinical application.
PG  - 789814
LID - 10.1155/2013/789814 [doi]
LID - 789814
AB  - The gut mucosa undergoes continuous antigenic exposure from food antigens, 
      commensal flora derived ligands, and pathogens. This constant stimulation results 
      in controlled inflammatory responses that are effectively suppressed by multiple 
      factors. This tight regulation, necessary to maintain intestinal homeostasis, is 
      affected during inflammatory bowel diseases (IBD) resulting in altered immune 
      responses to harmless microorganisms. Dendritic cells (DCs) are sentinels of 
      immunity, located in peripheral and lymphoid tissues, which are essential for 
      homeostasis of T cell-dependent immune responses. The expression of a particular 
      set of pathogen recognition receptors allows DCs to initiate immune responses. 
      However, in the absence of danger signals, different DC subsets can induce active 
      tolerance by inducing regulatory T cells (Treg), inhibiting inflammatory T helper 
      cell responses, or both. Interestingly, several protocols to generate clinical 
      grade tolerogenic DC (tol-DCs) in vitro have been described, opening the 
      possibility to restore the intestinal homeostasis to bacterial flora by cellular 
      therapy. In this review, we discuss different DC subsets and their role in IBD. 
      Additionally, we will review preclinical studies performed in animal models while 
      describing recent characterization of tol-DCs from Crohn's disease patients for 
      clinical application.
FAU - Cabezon, Raquel
AU  - Cabezon R
AD  - Fundacio Clinic, Hospital Clinic i Provincial and Centre Esther Koplowitz, 08036 
      Barcelona, Spain.
FAU - Benitez-Ribas, Daniel
AU  - Benitez-Ribas D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131112
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Antigens)
SB  - IM
MH  - Animals
MH  - Antigens/immunology
MH  - Crohn Disease/immunology/therapy
MH  - Dendritic Cells/*immunology/metabolism
MH  - Disease Models, Animal
MH  - Humans
MH  - *Immune Tolerance
MH  - Immunotherapy
MH  - Inflammatory Bowel Diseases/*immunology/therapy
MH  - Phenotype
PMC - PMC3844279
EDAT- 2013/12/10 06:00
MHDA- 2014/06/10 06:00
PMCR- 2013/11/12
CRDT- 2013/12/10 06:00
PHST- 2013/07/26 00:00 [received]
PHST- 2013/09/27 00:00 [accepted]
PHST- 2013/12/10 06:00 [entrez]
PHST- 2013/12/10 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
PHST- 2013/11/12 00:00 [pmc-release]
AID - 10.1155/2013/789814 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2013;2013:789814. doi: 10.1155/2013/789814. Epub 2013 Nov 12.